Whispering in the Wind (WITW 91) September 30, 2015
Ethics and good, responsible ethical behavior in the business
world has turned particularly sour in the last while and should be exposed for
what it is.
Volkswagen
Martin Winterkorn, CEO of Germany’s Volkswagen Group
resigned a few weeks ago when it was revealed that people in the company conspired
to defraud the public and governments by adding illegal engineered devices to
their diesel products and were able to report lower nitrogen oxide emissions
than what actually existed. While the
conspiracy rests solely within Volkswagen’s senior management organization, it
will cost the company big time in terms of lost reputation, many billions of
dollars in fines and lawsuits and jail time for those held responsible. The Volkswagen scandal is clearly a wake-up
call for national governments around the world and their need for better
oversight and regulation of so called globalized companies – where some globalized
companies appear to have lost respect for national laws and the most basic ethical
standards are considered irrelevant in the pursuit of market share and profit. Volkswagen is ranked by Forbes Magazine to be
the world’s 8th largest firm in terms of sales revenue and is the
second largest automaker.
KPMG
KPMG LLP is one of the world’s largest accounting – audit
– tax advisory service firms and has in recent years suffered for promoting
illegal tax shelter fraud schemes in the United States. In 2007 the firm admitted to criminal wrong
doing by creating tax shelters for wealthy US citizens to avoid billions of
dollars in United States taxes. Through
a “deferred prosecution agreement” KPMG LLP paid a fine of US$456 million. KPMG
Canada is also embroiled in its own tax avoidance scheme. Canada’s revenue agency is investigating a
KPMG tax avoidance scheme that the government deems to be “grossly negligent”
and a “sham”. In early 2013 a federal
court judge ordered KPMG to turn over a list of Canadian millionaires who
(through KPMG) invested fortunes in an Isle of Man tax shelter scheme that the
Canada Revenue Agency (CRA) is calling a “sham”. According to court documents: a family in
British Columbia gave $26 million to an arm’s length company (structured by
KPMG) on the Isle of Man and the family in turn was “gifted” back the original
investment without incurring any taxes in Canada – no question in my mind, the
Canada Revenue Agency is seeking the names of other KPMG clients who might have
taken advantage of the Isle of Man scheme – the Federal Court agrees. KPMG has called the court order a “fishing
expedition” while at the same time appears to be negotiating with the Canada
Revenue Agency on a settlement similar to the “deferred prosecution agreement”
in the United States. As to whether the
scheming and actions of KPMG Canada was ethical by Canadian standards and laws
is a good question, I doubt Canadians will ever be told or know?
Martin Shkreli
Until recently Martin Shkreli was a little known
entrepreneur who knew how to make a lot of money in the stock market. Today Mr. Shkreli has been labeled America’s
“icon of greed” and by some, “America’s most hated man”. Mr. Shkreli is the man who took a drug that
he purchased the rights to and increased the price of the drug 4,000 percent. Mr. Shkreli then in an interview, called his
action “altruistic” – altruism meaning behavior that shows a desire to help
other people and a lack of selfishness.
Later Mr. Shkreli has had second thoughts about his business model and
said he would be reducing the price of his patented drug but would not disclose
the reduced price. If there is a benefit
to Mr. Shkreli’s outrageous actions, it might prompt governments to take action
and regulate pricing in the pharmaceutical industry.
Alexion Pharmaceuticals
United States based Alexion Pharmaceuticals has recently taken
Canadian authorities to court for the government’s attempt to lower the price
of Soliris, a drug produced by Alexion to treat very rare blood disorders. Soliris has been labeled the world’s most
expensive drug. Alexion Pharmaceuticals has
been very vague on justifying the high cost of the drug and some researchers
claim that 80 to 90 percent of the development costs for drugs like Soliris are
actually born by universities and other publically research groups. Kelly Crowe of the CBC News organization has
concluded: “. . . Alexion sets the price
of Soliris at a half a million dollars a year because that’s what it thinks the
market will bear, based on the fact that the drug works and patients have no
other treatment options. . . .The business model depends on public health-care
systems and private insurance companies reimbursing the million-dollar drug
bills.” It is worthy to note that
Alexion’s sole product is the Soliris drug and in just 8 years generated $6
billion in revenue. Alexion is one of
the fastest growing drug companies in the world with a business model that
lacks a code of ethics that is normally attached to those in the healthcare
industry. My perspective, actions like
Alexion could be a major factor that threatens a reasonable healthcare system
in Canada and elsewhere.